CRBU vs. INO
CRBU (Caribou Biosciences, Inc.) and INO (Inovio Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, CRBU returned -27.65%/yr vs -40.23%/yr for INO. At a 0.46 correlation, their price movements are largely independent.
Performance
CRBU vs. INO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CRBU achieves a 3.14% return, which is significantly higher than INO's -36.21% return.
CRBU
- 1D
- 0.00%
- 1M
- -21.90%
- YTD
- 3.14%
- 6M
- -4.65%
- 1Y
- 22.39%
- 3Y*
- -27.65%
- 5Y*
- —
- 10Y*
- —
INO
- 1D
- -0.45%
- 1M
- -17.78%
- YTD
- -36.21%
- 6M
- -50.67%
- 1Y
- -43.37%
- 3Y*
- -40.23%
- 5Y*
- -59.69%
- 10Y*
- -36.85%
CRBU vs. INO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CRBU Caribou Biosciences, Inc. | 3.14% | 0.00% | -72.25% | -8.76% | -58.38% | -14.50% |
INO Inovio Pharmaceuticals, Inc. | -36.21% | -4.92% | -70.10% | -67.31% | -68.74% | -42.25% |
Correlation
The correlation between CRBU and INO is 0.42, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.42 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.41 |
Correlation (All Time) Calculated using the full available price history since Jul 23, 2021 | 0.46 |
Fundamentals
CRBU:
$157.21M
INO:
$767.03M
CRBU:
-$1.41
INO:
-$63.15
CRBU:
1.54
INO:
0.13
CRBU:
$8.81M
INO:
$0.00
CRBU:
$7.49M
INO:
-$1.50M
CRBU:
-$115.23M
INO:
-$22.01B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CRBU vs. INO — Risk / Return Rank
CRBU
INO
CRBU vs. INO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Caribou Biosciences, Inc. (CRBU) and Inovio Pharmaceuticals, Inc. (INO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CRBU | INO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.77 | ||
| Sortino ratioReturn per unit of downside risk | +1.22 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 0.97 | +0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.44 | -0.69 | +1.13 |
| Martin ratioReturn relative to average drawdown | 0.75 | -1.11 | +1.85 |
Loading charts...
Drawdowns
CRBU vs. INO - Drawdown Comparison
The maximum CRBU drawdown since its inception was -97.58%, roughly equal to the maximum INO drawdown of -99.95%. Use the drawdown chart below to compare losses from any high point for CRBU and INO.
Loading charts...
Drawdown Indicators
| CRBU | INO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.58% | -99.95% | +2.37% |
Max Drawdown (1Y)Largest decline over 1 year | -51.06% | -63.41% | +12.35% |
Max Drawdown (3Y)Largest decline over 3 years | -91.12% | -92.44% | +1.32% |
Max Drawdown (5Y)Largest decline over 5 years | — | -99.10% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -99.72% | — |
Current DrawdownCurrent decline from peak | -94.59% | -99.95% | +5.36% |
Average DrawdownAverage peak-to-trough decline | -79.38% | -92.35% | +12.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.02% | 39.27% | -9.25% |
Volatility
CRBU vs. INO - Volatility Comparison
Caribou Biosciences, Inc. (CRBU) has a higher volatility of 23.10% compared to Inovio Pharmaceuticals, Inc. (INO) at 16.85%. This indicates that CRBU's price experiences larger fluctuations and is considered to be riskier than INO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CRBU | INO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 23.10% | 16.85% | +6.25% |
Volatility (6M)Calculated over the trailing 6-month period | 50.00% | 64.19% | -14.19% |
Volatility (1Y)Calculated over the trailing 1-year period | 81.71% | 87.98% | -6.27% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 86.66% | 85.67% | +0.99% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 86.66% | 93.33% | -6.67% |
Dividends
CRBU vs. INO - Dividend Comparison
Neither CRBU nor INO has paid dividends to shareholders.
Financials
CRBU vs. INO - Financials Comparison
This section allows you to compare key financial metrics between Caribou Biosciences, Inc. and Inovio Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CRBU and INO have a correlation of 0.42, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CRBU has higher volatility (23.10%) compared to INO (16.85%). In terms of maximum drawdown, CRBU dropped -97.58% vs INO's -99.95%.
CRBU currently has the higher Sharpe Ratio (0.28 vs -0.50), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CRBU and INO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer